Arcturus Therapeutics Holdings Inc. (ARCT) Stock Analysis
ARCT offers highly asymmetric speculative upside as Vertex’s VX-522 exit leaves ARCT-032 alone in inhaled mRNA CF, but clinical failure, CSL disruption and dilution remain material risks.
Overview
Arcturus Therapeutics is a clinical-stage biotechnology company transitioning from partner-funded COVID vaccine development toward high-value orphan genetic medicines. Its LUNAR lipid platform and STARR sa-mRNA technology support two principal assets: inhaled ARCT-032 for Class I cystic fibrosis and intravenous ARCT-810 for OTC deficiency; KOSTAIVE remains commercialized in Japan by Meiji. **The central investment catalyst is Vertex’s May 4, 2026 termination of VX-522 after localized lung inflammation, leaving ARCT-032 with an apparently uncontested inhaled mRNA CF position.** Arcturus also entered an $80 million Thermo Fisher collaboration, split between Patheon manufacturing and PPD clinical execution, reducing Phase III implementation risk. Financially, Q1 2026 revenue fell 92.99% to $2.06 million and missed $6.30 million consensus, while net loss widened to $27.0 million, although EPS of $(0.95) beat expectations by $0.06. Cash of $213.4 million supports milestones beyond Q2 2028. The report values the shares through pipeline rNPV rather than trailing multiples: base FY2031 revenue of $270 million supports a $30.00 share price, while the probability-weighted target is $43.57 versus the $7.39 reference price. Near-term catalysts are ARCT-032 Phase II ppFEV1/LCI data in late 2026 and FDA alignment for the ARCT-810 pediatric pivotal pathway in H2 2026.